Utility of High Resolution NMR Methods to Probe the Impact of Chemical Modifications on Higher Order Structure of Monoclonal Antibodies in Relation to Antigen Binding.
deamidation
higher order structure (HOS)
monoclonal antibodies
nuclear magnetic resonance
potency
Journal
Pharmaceutical research
ISSN: 1573-904X
Titre abrégé: Pharm Res
Pays: United States
ID NLM: 8406521
Informations de publication
Date de publication:
01 Jul 2019
01 Jul 2019
Historique:
received:
29
03
2019
accepted:
24
05
2019
entrez:
3
7
2019
pubmed:
3
7
2019
medline:
31
8
2019
Statut:
epublish
Résumé
An understanding of higher order structure (HOS) of monoclonal antibodies (mAbs) could be critical to predicting its function. Amongst the various factors that can potentially affect HOS of mAbs, chemical modifications that are routinely encountered during production and long-term storage are of significant interest. To this end, two Pfizer mAbs were subjected to forced deamidation stress for a period of eight weeks. Samples were aliquoted at various time points and high resolution accurate mass liquid chromatography-mass spectrometry (LC-MS/MS) was performed using low-artifact trypsin digestion (LATD) peptide mapping to identify and quantify chemical modifications. 2D backbone amide and sidechain methyl NMR spectra were acquired to gauge the effect of HOS changes upon chemical modification. Differential scanning calorimetry was also performed to assess the effect of thermal stability of mAbs upon modification. Finally, functional studies via target-binding based ELISA were performed to connect HOS changes to any loss of potency. The extent of deamidation in the mAb domains were quantified by LC-MS/MS. The HOS changes as obtained from 2D NMR were mostly localized around the affected sites leaving the overall structure relatively unchanged. The antigen-antibody binding of the mAbs, in spite of deamidation in the Fab region, remains unchanged. This case study provides an integrated approach of relating chemical modifications in mAb domains with possible changes in HOS. This can be potentially used to assess a possible loss of potency within the structure-function paradigm of proteins in an orthogonal manner.
Identifiants
pubmed: 31264003
doi: 10.1007/s11095-019-2652-1
pii: 10.1007/s11095-019-2652-1
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antigen-Antibody Complex
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
130Références
J Cancer Res Clin Oncol. 1999;125(3-4):182-6
pubmed: 10235472
Protein Sci. 1999 Nov;8(11):2519-23
pubmed: 10595558
Protein Sci. 2000 Nov;9(11):2260-8
pubmed: 11152137
Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):944-9
pubmed: 11158575
J Chromatogr B Biomed Sci Appl. 2001 Mar 10;752(2):233-45
pubmed: 11270864
Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12409-13
pubmed: 11606750
J Biol Chem. 2002 Aug 23;277(34):30502-7
pubmed: 12068021
J Biol Chem. 2003 Apr 25;278(17):15142-52
pubmed: 12554741
Anal Chem. 1992 Sep 1;64(17):1864-70
pubmed: 1416039
Anal Chem. 2005 Mar 1;77(5):1432-9
pubmed: 15732928
Anal Chem. 2005 Sep 15;77(18):6004-11
pubmed: 16159134
Electrophoresis. 1992 Apr;13(4):214-9
pubmed: 1628601
Crit Rev Biochem Mol Biol. 1991;26(1):1-52
pubmed: 1678690
J Pharm Sci. 2007 Jan;96(1):1-26
pubmed: 16998873
Pharm Res. 2007 Jun;24(6):1145-56
pubmed: 17385019
Anal Biochem. 1991 Feb 1;192(2):384-91
pubmed: 1827964
Biochemistry. 2008 May 6;47(18):5088-100
pubmed: 18407665
J Biol Chem. 1991 Jul 25;266(21):13544-7
pubmed: 1856190
Protein Sci. 2008 Sep;17(9):1565-75
pubmed: 18567786
Rapid Commun Mass Spectrom. 2008 Dec;22(24):4081-8
pubmed: 19021137
J Pharm Sci. 2009 Oct;98(10):3509-21
pubmed: 19475547
Anal Biochem. 2009 Sep 15;392(2):145-54
pubmed: 19497295
Protein Sci. 2009 Aug;18(8):1573-84
pubmed: 19544580
Biologicals. 2009 Oct;37(5):313-22
pubmed: 19608432
Mol Cell Proteomics. 2010 Aug;9(8):1716-28
pubmed: 20103567
MAbs. 2010 May-Jun;2(3):299-308
pubmed: 20404551
Anal Chem. 2010 Aug 1;82(15):6363-9
pubmed: 20669991
MAbs. 2010 Nov-Dec;2(6):613-24
pubmed: 20818176
Nat Chem Biol. 2011 Mar;7(3):147-53
pubmed: 21258329
J Biol Chem. 2011 Jul 15;286(28):25134-44
pubmed: 21518762
J Biol Chem. 2012 Jan 6;287(2):1381-96
pubmed: 22084250
PLoS One. 2012;7(1):e30295
pubmed: 22272329
Anal Chem. 2012 Jun 5;84(11):4942-9
pubmed: 22571272
J Pharm Sci. 2013 Jun;102(6):1712-1723
pubmed: 23568760
J Biochem. 2013 Oct;154(4):333-40
pubmed: 23853311
Science. 1986 Aug 15;233(4765):747-53
pubmed: 2426778
Anal Chem. 2014 Apr 1;86(7):3468-75
pubmed: 24597564
AAPS J. 2014 Jul;16(4):771-83
pubmed: 24854893
Proc Natl Acad Sci U S A. 2014 Jul 1;111(26):E2656-65
pubmed: 24938786
PLoS One. 2014 Jun 24;9(6):e100736
pubmed: 24959685
Biomol NMR Assign. 2015 Oct;9(2):257-60
pubmed: 25291979
Anal Chem. 2015 Apr 7;87(7):3556-61
pubmed: 25728213
Biochemistry. 2015 Aug 11;54(31):4890-9
pubmed: 26158710
Anal Chem. 2016 Feb 16;88(4):2041-50
pubmed: 26824491
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):944-949
pubmed: 28096333
Anal Chem. 2017 Aug 15;89(16):8233-8237
pubmed: 28700824
PLoS One. 2017 Jul 21;12(7):e0181347
pubmed: 28732052
FEBS Open Bio. 2017 Sep 05;7(10):1557-1574
pubmed: 28979843
MAbs. 2018 Feb/Mar;10(2):183-203
pubmed: 29300693
PLoS One. 2018 Feb 6;13(2):e0192123
pubmed: 29408873
Pharm Res. 2018 Sep 25;35(11):220
pubmed: 30255351
J Pharm Biomed Anal. 2019 Jan 30;163:144-152
pubmed: 30296716
MAbs. 2019 Jan;11(1):45-57
pubmed: 30526254
MAbs. 2019 Jan;11(1):94-105
pubmed: 30570405
Science. 1988 Apr 8;240(4849):191-4
pubmed: 3353715
Int J Pept Protein Res. 1987 Dec;30(6):808-21
pubmed: 3440704
J Biol Chem. 1987 Jan 15;262(2):785-94
pubmed: 3805008
J Biol Chem. 1984 Sep 10;259(17):10714-21
pubmed: 6088513
Pharm Res. 1994 May;11(5):751-8
pubmed: 8058648
FEBS Lett. 1993 May 3;322(1):69-72
pubmed: 8482371
J Pharm Sci. 1997 Nov;86(11):1250-5
pubmed: 9383735
Protein Sci. 1998 Feb;7(2):457-69
pubmed: 9521123